{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Checkpoint+Therapy&page=2", "query": { "condition": "Immune Checkpoint Therapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Checkpoint+Therapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T16:43:49.284Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05549297", "title": "Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Tebentafusp", "type": "DRUG" }, { "name": "Tebentafusp with Pembrolizumab", "type": "DRUG" }, { "name": "Investigators Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2022-12-19", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05549297" }, { "nct_id": "NCT03035890", "title": "Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Immuno-Therapeutic Agent", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-01-23", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03035890" }, { "nct_id": "NCT06635954", "title": "A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Immunotherapy", "PD-1", "PD-L1", "Immune Checkpoint Therapy" ], "interventions": [], "intervention_types": [], "sponsor": "Oxford Biodynamics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2024-05-14", "completion_date": "2027-05-14", "has_results": false, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 3, "location_summary": "Norwich, Connecticut • Dublin, Georgia • Rock Hill, South Carolina", "locations": [ { "city": "Norwich", "state": "Connecticut" }, { "city": "Dublin", "state": "Georgia" }, { "city": "Rock Hill", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06635954" }, { "nct_id": "NCT04965454", "title": "Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable" ], "interventions": [ { "name": "Fluorine-18 fluorocholine", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Queen's Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2022-03-28", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT04965454" }, { "nct_id": "NCT04751396", "title": "Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ankylosing Spondylitis", "Autoimmune Disease", "Crohn Disease", "Enteropathic Arthritis", "Enteropathic Spondylitis", "Inflammatory Bowel Disease", "Melanoma", "Psoriasis", "Psoriatic Arthritis", "Reactive Arthritis", "Rheumatoid Arthritis", "Systemic Lupus Erythematosus", "Ulcerative Colitis" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Interview", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2022-04-20", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04751396" }, { "nct_id": "NCT04560686", "title": "Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Lung Non-Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Bintrafusp Alfa", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-08-05", "completion_date": "2021-07-01", "has_results": true, "last_update_posted_date": "2022-07-28", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04560686" }, { "nct_id": "NCT04045613", "title": "Derazantinib and Atezolizumab in Patients With Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Derazantinib 300 mg once daily monotherapy", "type": "DRUG" }, { "name": "Derazantinib 200 mg once daily + atezolizumab 1200 mg", "type": "DRUG" }, { "name": "Derazantinib 300 mg once daily + atezolizumab 1200 mg", "type": "DRUG" }, { "name": "Derazantinib 200 mg twice daily + atezolizumab 1200 mg", "type": "DRUG" }, { "name": "Derazantinib 300 mg once daily monotherapy (QD)", "type": "DRUG" }, { "name": "Derazantinib 200 mg twice daily monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2019-08-02", "completion_date": "2022-10-04", "has_results": true, "last_update_posted_date": "2023-10-13", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 7, "location_summary": "Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more", "locations": [ { "city": "Newnan", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Port Jefferson Station", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04045613" }, { "nct_id": "NCT04571398", "title": "A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "ApricityRx mobile application", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Apricity Health, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2019-11-19", "completion_date": "2023-10-15", "has_results": false, "last_update_posted_date": "2020-10-01", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04571398" }, { "nct_id": "NCT03958045", "title": "Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Rucaparib and Nivolumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Zhonglin Hao", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-09-04", "completion_date": "2022-11-15", "has_results": true, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958045" }, { "nct_id": "NCT05967533", "title": "The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Renal Cell Carcinoma", "Advanced Triple-Negative Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer (AJCC) v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Fermented Wheat Germ Extract", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-06-02", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-07-22T16:43:49.284Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05967533" } ] }